Consolidated Entities - Pulmoquine Therapeutics, Inc. (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2021	Apr. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Consolidated Entities
Total assets	$ 887,239		$ 887,239		$ 887,239		$ 999,570	[1]
Operating Expenses			3,309	$ 4,264	13,610	$ 9,982
Pulmoquine Therapeutics, Inc.
Consolidated Entities
Proceeds from net distribution on dissolution of Pulmoquine	2,300
Total assets	$ 200		200		200		$ 3,500
Operating Expenses			$ 500	$ 1,100	$ 700	$ 1,700
Pulmoquine Therapeutics, Inc. | Series A preferred stock
Consolidated Entities
Number of shares purchased under the securities purchase agreement		5,808,550
Payments to acquire equity securities		$ 5,000

[1] Consolidated balance sheet as of December 31, 2020 has been derived from audited consolidated financial statements.